Your browser doesn't support javascript.
loading
The dual PPARα/γ agonist aleglitazar increases the number and function of endothelial progenitor cells: implications for vascular function and atherogenesis.
Werner, C M; Schirmer, S H; Gensch, C; Pavlickova, V; Pöss, J; Wright, M B; Böhm, M; Laufs, U.
Afiliação
  • Werner CM; Klinik für Innere Medizin III (Kardiologie, Angiologie und Internistische Intensivmedizin), Universitätsklinikum des Saarlandes, Homburg/Saar, Germany.
Br J Pharmacol ; 171(10): 2685-703, 2014 May.
Article em En | MEDLINE | ID: mdl-24467636
ABSTRACT
BACKGROUND AND

PURPOSE:

Aleglitazar is a dual PPARα/γ agonist but little is known about its effects on vascular function and atherogenesis. Hence, we characterized its effects on circulating angiogenic cells (CAC), neoangiogenesis, endothelial function, arteriogenesis and atherosclerosis in mice. EXPERIMENTAL

APPROACH:

C57Bl/6 wild-type (WT, normal chow), endothelial NOS (eNOS)(-/-) (normal chow) and ApoE(-/-) (Western-type diet) mice were treated with aleglitazar (10 mg·kg(-1) ·day(-1) , i.p.) or vehicle. KEY

RESULTS:

Aleglitazar enhanced expression of PPARα and PPARγ target genes, normalized glucose tolerance and potently reduced hepatic fat in ApoE(-/-) mice. In WT mice, but not in eNOS(-/-) , aleglitazar up-regulated Sca-1/VEGFR2-positive CAC in the blood and bone marrow and up-regulated diLDL/lectin-positive CAC. Aleglitazar augmented CAC migration and enhanced neoangiogenesis. In ApoE(-/-) mice, aleglitazar up-regulated CAC number and function, reduced markers of vascular inflammation and potently improved perfusion restoration after hindlimb ischaemia and aortic endothelium-dependent vasodilatation. This was associated with markedly reduced formation of atherosclerotic plaques. In human cultured CAC from healthy donors and patients with coronary artery disease with or without diabetes mellitus, aleglitazar increased migration and colony-forming units in a concentration-dependent manner. Furthermore, oxidative stress-induced CAC apoptosis and expression of p53 were reduced, while telomerase activity and expression of phospho-eNOS and phospho-Akt were elevated. Comparative agonist and inhibitor experiments revealed that aleglitazar's effects on CAC migration and colony-forming units were mediated by both PPARα and PPARγ signalling and required Akt. CONCLUSIONS AND IMPLICATIONS Aleglitazar augments the number, function and survival of CAC, which correlates with improved vascular function, enhanced arteriogenesis and prevention of atherosclerosis in mice.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oxazóis / Células-Tronco / Tiofenos / Músculo Esquelético / Células Endoteliais / PPAR alfa / PPAR gama / Proliferação de Células / Aterosclerose / Isquemia Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Revista: Br J Pharmacol Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oxazóis / Células-Tronco / Tiofenos / Músculo Esquelético / Células Endoteliais / PPAR alfa / PPAR gama / Proliferação de Células / Aterosclerose / Isquemia Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Revista: Br J Pharmacol Ano de publicação: 2014 Tipo de documento: Article